Related Experiment Videos
Isoprinosine in classical acute viral hepatitis
The American Journal of Digestive Diseases
|October 1, 1978
Summary
Isoprinosine showed no therapeutic benefit for acute viral hepatitis in a controlled study. This antiviral drug was ineffective in improving patient recovery or biochemical markers during the acute phase.
Area of Science:
- Hepatology
- Virology
- Clinical Pharmacology
Background:
- Acute viral hepatitis is a significant global health concern.
- Isoprinosine has been investigated for antiviral properties.
- Preliminary reports suggested potential benefits of isoprinosine in viral hepatitis.
Purpose of the Study:
- To evaluate the efficacy of isoprinosine in treating classical acute viral hepatitis.
- To assess the impact of isoprinosine on clinical and biochemical parameters of acute viral hepatitis patients.
Main Methods:
- A prospective, double-blind, controlled study involving 81 patients.
- Daily appetite assessment and weekly monitoring of liver enzymes (ALT, AST) and bilirubin.
- Comparison of treatment groups regarding biochemical recovery, mortality, and symptom resolution over 4 weeks.
Main Results:
- No significant therapeutic benefit of isoprinosine was observed across all assessed parameters.
- Isoprinosine did not improve liver enzyme levels, reduce mortality, or accelerate appetite recovery.
- Treatment with isoprinosine did not prevent a rise in aminotransferase levels in some patients.
Conclusions:
- Isoprinosine is ineffective for treating classical acute viral hepatitis during its acute phase.
- The study contradicts earlier preliminary findings on isoprinosine's efficacy.
- Further research may be needed to explore alternative treatments for acute viral hepatitis.